Yıl: 2022 Cilt: 13 Sayı: 1 Sayfa Aralığı: 32 - 42 Metin Dili: İngilizce DOI: 10.37678/dcybd.2022.2942 İndeks Tarihi: 16-06-2022

Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model

Öz:
Objective: In various pathophysiological conditions, including septic shock, reactive oxidants cause DNA strand breakage and subsequent activation of the nuclear enzyme poly (ADP ribose) polymerase (PARP). Activation of PARP results in cellular dysfunction. We investigated the 3-Aminobenzamide (3-AB), one of the pure PARP-1 inhibitor, on mesenteric blood flow and organ injury (lung, liver, spleen) in a murine caecal ligation and puncture (CLP) model of septic shock in both gender. Methods: Female and male Swiss albino mice received 3-AB (10 mg/kg, i.p.) or its solvent saline (0.9% NaCl, w/v) 1 hour after CLP. At 24th hour, the animals were anaesthetized with chloralhydrate (400 mg kg-1, i.p.) and the mesenteric blood flow was monitored for 15 min by using perivascular ultrasonic Doppler-flowmeter. Then the animals were exsanguinated, spleen, liver, and kidneys were isolated accordingly for histopathological examination. Thiobarbituric acid-reacting substances, glutathione and myeloperoxides activities were also determined in tissues. Results: Although the glutathione levels were decreased and thiobarbituric acid-reacting substances and myeloperoxidase activity were increased by CLP in lung and liver, 3-AB has failed to block these biochemical parameters. In CLP + saline group, the mesenteric arterial blood flow was significantly lower than that of saline group (p<0.0001). 3-AB administration, did not prevent this status. 3-AB also did not attenuate the histopathological injury inflicted by CLP. Conclusion: Poly (ADP-ribose) polymerase-1 inhibitor 3-AB, controversial to the common results of the recent literature, has no significant effect on splanchnic ischemia or multiple organ injury as histopathogically or biochemically in both gender.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999;340:207–14. [CrossRef]
  • 2. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113:227–42. [CrossRef]
  • 3. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10. [CrossRef]
  • 4. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457– 469. [CrossRef]
  • 5. Iskit AB, Guc O. Effects of endothelin and nitric oxide on organ injury, mesenteric ischemia, and survival in experimental models of septic shock. Acta Pharmacol Sin. 2003;24:953–57. http://www. chinaphar.com/article/view/9046
  • 6. Iskit AB, Sungur A, Gedikoglu G, et al. The effects of bosentan, aminoguanidine and L-canavanine on mesenteric blood flow, spleen and liver in endotoxaemic mice. Eur J Pharmacol. 1999;379:73–80. [CrossRef]
  • 7. Erdem A, Sevgili AM, Akbiyik F, et al. The effect of taurine on mesenteric blood flow and organ injury in sepsis. Amino Acids. 2008;35:403–10. [CrossRef]
  • 8. Villa P, Sartor G, Angelini M, et al. Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol. 1995;2:549–53. [CrossRef]
  • 9. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock--a review of laboratory models and a proposal. J Surg Res. 1980;29:189– 201. [CrossRef]
  • 10. Bai P. Biology of poly (ADP-ribose) polymerases: the factotums of cell maintenance. Mol Cell. 2015;58:947–958. [CrossRef]
  • 11. Pazzaglia S, Pioli C. Multifaceted role of PARP-1 in DNA repair and inflammation: pathological and therapeutic implications in cancer and non-cancer diseases. Cells. 2019;9. [CrossRef]
  • 12. Fehr AR, Singh SA, Kerr CM, et al. The impact of PARPs and ADPribosylation on inflammation and host-pathogen interactions. Genes Dev. 2020;34:341–59. [CrossRef]
  • 13. Durkacz BW, Omidiji O, Gray DA, et al. (ADP-ribose) n participates in DNA excision repair. Nature. 1980;283:593–96. [CrossRef]
  • 14. Satoh MS, Lindahl T. Role of poly (ADP-ribose) formation in DNA repair. Nature. 1992;356;356–58. [CrossRef]
  • 15. Althaus FR, Richter C. ADP-ribosylation of proteins. Enzymology and biological significance. Mol Biol Biochem Biophys. 1987;37:1– 237. [CrossRef]
  • 16. Lindahl T, Satoh MS., Poirier GG, et al. Post-translational modification of poly (ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci. 1995;20:405–11. [CrossRef]
  • 17. Sims JL, Berger SJ, Berger NA. Poly (ADP-ribose) Polymerase inhibitors preserve nicotinamide adenine dinucleotide and adenosine 5’-triphosphate pools in DNA-damaged cells: mechanism of stimulation of unscheduled DNA synthesis. Biochemistry. 1983;22:5188–94. [CrossRef]
  • 18. Aberle L, Krüger A, Reber JM, et al. PARP1 catalytic variants reveal branching and chain length-specific functions of poly (ADPribose) in cellular physiology and stress response. Nucleic Acids Res. 2020;48:10015–33. [CrossRef]
  • 19. Palfi A, Toth A, Kulcsar G, et al. The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly (ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenoldamaged rat hearts. J Pharmacol Exp Ther. 2005;315:273–82. [CrossRef]
  • 20. Aguilar-Quesada R, Munoz-Gamez JA, Martin-Oliva D, et al. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem. 2007;14 1179–87. [CrossRef]
  • 21. Oliver FJ, Menissier-de Murcia J, Nacci C, et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J. 1999;18:4446–54. [CrossRef]
  • 22. Liaudet L, Szabo A, Soriano FG, et al. Poly (ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia. Shock. 2000;14:134–41. [CrossRef]
  • 23. Szabo C, Zingarelli B, O’Connor M, et al. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A. 1996;93:1753–8. [CrossRef]
  • 24. Szabo C, Virag L, Cuzzocrea S, et al. Protection against peroxynitriteinduced fibroblast injury and arthritis development by inhibition of poly (ADP-ribose) synthase. Proc Natl Acad Sci U S A. 1998;95:3867–72. [CrossRef]
  • 25. Liaudet L, Soriano FG, Szabo E, et al. Protection against hemorrhagic shock in mice genetically deficient in poly (ADP-ribose) polymerase. Proc Natl Acad Sci U S A. 2000;97:10203–8. [CrossRef]
  • 26. Sethi, G, Sodhi A. Role of p38 mitogen-activated protein kinase and caspases in UV-B-induced apoptosis of murine peritoneal macrophages. Photochem Photobiol 2004;79:48–54. [CrossRef]
  • 27. Sarker M, Ruiz-Ruiz C, Lopez-Rivas A. Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line. Cell Death Differ. 2001;8:172–81. [CrossRef]
  • 28. Tempel K, von Zallinger C. Caffeine-DNA interactions: biochemical investigations comprising DNA-repair enzymes and nucleic acid synthesis. Z Naturforsch [C]. 1997;52:466–74. [CrossRef]
  • 29. Garcia-Bermejo L, Perez C, Vilaboa NE, et al. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J Cell Sci. 1998;111(Pt 5):637–44. [CrossRef]
  • 30. Kamaletdinova T, Fanaei-Kahrani Z, Wang Z-Q. The enigmatic function of PARP1: from PARylation activity to PAR readers. Cells. 2019;8:1625. [CrossRef]
  • 31. Tanaka Y, Yoshihara K, Tohno Y, et al. Inhibition and down-regulation of poly (ADP-ribose) polymerase results in a marked resistance of HL60 cells to various apoptosis-inducers. Cell Mol Biol (Noisy-le-grand) 1995;41:771–81. https://pubmed.ncbi.nlm.nih.gov/8535170/
  • 32. McCullough LD, Zeng Z, Blizzard KK, et al. Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab. 2005;25:502–12. [CrossRef]
  • 33. Mabley JG, Horvath EM, Murthy KG, et al. Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly (ADP-ribose) polymerase activation. J Pharmacol Exp Ther. 2005;315:812–20. [CrossRef]
  • 34. Iskit AB, Senel I, Sokmensuer C, et al. Endothelin receptor antagonist bosentan improves survival in a murine caecal ligation and puncture model of septic shock. Eur J Pharmacol. 2004;506:83–8. [CrossRef]
  • 35. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86:271–8. [CrossRef]
  • 36. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27:502– 22. [CrossRef]
  • 37. Akbiyik F, Demirpence E, Kuzu M, et al. In vitro and in vivo inhibition of myeloperoxidase with 5-fluorouracil. Eur J Clin Pharmacol. 2001;57:631–6. [CrossRef]
  • 38. Baykal A, Iskit AB, Kaynaroglu V, et al. Effects of adrenaline or endotoxin tolerance states on mesenteric blood flow in endotoxaemia. Aust N Z J Surg. 1999;69:134–7. [CrossRef]
  • 39. Baykal A, Iskit AB, Hamaloglu E, et al. Melatonin modulates mesenteric blood flow and TNFalpha concentrations after lipopolysaccharide challenge. Eur J Surg. 2000;166:722–7. [CrossRef]
  • 40. Baykal A, Kavuklu B, Iskit AB, et al. Experimental study of the effect of nitric oxide inhibition on mesenteric blood flow and interleukin-10 levels with a lipopolysaccharide challenge. World J Surg. 2000; 24:1116–20. [CrossRef]
  • 41. Kavuklu B, Iskit AB, Guc MO, et al. Aminoguanidine attenuates endotoxin-induced mesenteric vascular hyporeactivity. Br J Surg. 2000;87:448–53. [CrossRef]
  • 42. Wasyluk W, Zwolak A. PARP inhibitors: An Innovative approach to the treatment of inflammation and metabolic disorders in sepsis. J Inflam Res. 2021;14:1827–44. [CrossRef]
  • 43. Soriano FG, Liaudet L, Szabo E, et al. Resistance to acute septic peritonitis in poly (ADP-ribose) polymerase-1-deficient mice. Shock. 2002;17:286–92. [CrossRef]
  • 44. Goldfarb RD, Marton A, Szabo E, et al. Protective effect of a novel, potent inhibitor of poly (adenosine 5’-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med. 2002;30:974–80. [CrossRef]
  • 45. Abdelkarim GE, Gertz K, Harms C, et al. Protective effects of PJ34, a novel, potent inhibitor of poly (ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med. 2001;7:255–60. [CrossRef]
  • 46. Wray GM, Hinds CJ, Thiemermann C. Effects of inhibitors of poly (ADP-ribose) synthetase activity on hypotension and multiple organ dysfunction caused by endotoxin. Shock. 1998;10:13–9. [CrossRef]
  • 47. Jagtap P, Soriano FG, Virag L, et al. Novel phenanthridinone inhibitors of poly (adenosine 5’-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med. 2002;30:1071–82. [CrossRef]
  • 48. Weltin D, Picard V, Aupeix K, et al. Immunosuppressive activities of 6(5H)-phenanthridinone, a new poly (ADP-ribose) polymerase inhibitor. Int J Immunopharmacol. 1995;17:265–71. [CrossRef]
  • 49. Hagberg H, Wilson MA, Matsushita H, et al. PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem. 2004;90:1068–75. [CrossRef]
APA serdar S, ATİLLA P, Iskit A (2022). Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. , 32 - 42. 10.37678/dcybd.2022.2942
Chicago serdar Selda,ATİLLA Pergin,Iskit Alper B. Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. (2022): 32 - 42. 10.37678/dcybd.2022.2942
MLA serdar Selda,ATİLLA Pergin,Iskit Alper B. Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. , 2022, ss.32 - 42. 10.37678/dcybd.2022.2942
AMA serdar S,ATİLLA P,Iskit A Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. . 2022; 32 - 42. 10.37678/dcybd.2022.2942
Vancouver serdar S,ATİLLA P,Iskit A Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. . 2022; 32 - 42. 10.37678/dcybd.2022.2942
IEEE serdar S,ATİLLA P,Iskit A "Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model." , ss.32 - 42, 2022. 10.37678/dcybd.2022.2942
ISNAD serdar, Selda vd. "Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model". (2022), 32-42. https://doi.org/10.37678/dcybd.2022.2942
APA serdar S, ATİLLA P, Iskit A (2022). Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. Journal of critical and intensive care (Online), 13(1), 32 - 42. 10.37678/dcybd.2022.2942
Chicago serdar Selda,ATİLLA Pergin,Iskit Alper B. Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. Journal of critical and intensive care (Online) 13, no.1 (2022): 32 - 42. 10.37678/dcybd.2022.2942
MLA serdar Selda,ATİLLA Pergin,Iskit Alper B. Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. Journal of critical and intensive care (Online), vol.13, no.1, 2022, ss.32 - 42. 10.37678/dcybd.2022.2942
AMA serdar S,ATİLLA P,Iskit A Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. Journal of critical and intensive care (Online). 2022; 13(1): 32 - 42. 10.37678/dcybd.2022.2942
Vancouver serdar S,ATİLLA P,Iskit A Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model. Journal of critical and intensive care (Online). 2022; 13(1): 32 - 42. 10.37678/dcybd.2022.2942
IEEE serdar S,ATİLLA P,Iskit A "Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model." Journal of critical and intensive care (Online), 13, ss.32 - 42, 2022. 10.37678/dcybd.2022.2942
ISNAD serdar, Selda vd. "Effects of PARP Inhibitör 3-Aminobenzamide on Impaired Mesenteric Blood Flow and Organ Injury in CLP-Induced Septic Shock Model". Journal of critical and intensive care (Online) 13/1 (2022), 32-42. https://doi.org/10.37678/dcybd.2022.2942